



REPO TRIAL

Optimisation of computerised (*in silico*) drug **RE**Purp**O**sing

Project duration
5 years

Grant amount
5,5 million €

4 Countries

Kick-off
01 February 2018

More information
www.repo-trial.eu

low cost & low risk

- potential side effects are already known
- *in silico* drug repurposing screens known drugs in mechanistically related diseases
- in comparison, *de novo* drug design has to start from scratch

precision & efficacy

- selection of predominant cerebro-cardiovascular patients with similar mechanistic biomarkers as those already targeted by the known drugs

fast approval & patient benefit

- approved drugs need less time for clinical validation of their newly intended purpose

less animal research

- meta-analyses of relevant preclinical publications reduce the number of animal experiment

scientific merit & future potential

- extending the knowledge regarding the mechanisms underlying specific cerebro-cardiovascular diseases
- personalized treatment based on individual biomarker profiles for each patient

